Drug Trial Radar · NCT05059106
EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19
Last checked: Nov 20, 2026Latest source record: Sep 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
29,637
Planned (sponsor's estimate)
Start
Jun 1, 2021
Primary completion
Jun 1, 2022
Study completion Oct 30, 2022
Sponsor
- Lead sponsor
- Federal University of Espirito SantoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Instituto René Rachou (IRR); Escola Nacional de Saúde Pública Sérgio Arouca/Fiocruz; Oswaldo Cruz Foundation; Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória
- First posted
- Sep 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is clinical trial (intervention study with external comparison group) to test vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years from Viana city - Espírito Santo (ES)/Brazil, on the incidence of new cases over 12 months following treatment, compared to an external group from same state and adjusted for socio-demographic and epidemiological variables.
Conditions
- SARS-CoV-2
Interventions
Half dose of ChAdOx1 nCoV-19 (AZD1222)Biological
Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.
Standard dose of ChAdOx1 nCoV-19 (AZD1222)Biological
Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of new casesTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Federal University of Espirito Santo
Vitória, Espírito Santo, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.